On Sep 27, major Wall Street analysts update their ratings for $Travere Therapeutic (TVTX.US)$, with price targets ranging from $18 to $23.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and adjusts the target price from $19 to $18.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $23 to $19.
Guggenheim analyst Vamil Divan maintains with a buy rating, and adjusts the target price from $25 to $23.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and adjusts the target price from $23 to $18.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Travere Therapeutics recently announced a halt to the enrollment of their pegtibatinase phase 3 HARMONY study due to manufacturing concerns. This development is seen as a delay to the commercial portfolio, with the company anticipating a possible resumption of the trial by 2026 at the earliest. Despite the setback, the value ascribed to the program was already minimal, and the company's management has conveyed that the halt is unlikely to affect the trial's design and enrollment. Consequently, the anticipated impact on market sentiment in the near term is expected to be limited.
Travere Therapeutics announced a voluntary suspension in the enrollment for their Phase 3 HARMONY study of pegtibatinase, attributed to challenges in manufacturing scale-up. This development is seen as a setback given that pegtibatinase was anticipated to expand the company's portfolio beyond Filspari. The anticipated market introduction has now been adjusted to fiscal 2030, with the assumption that enrollment will recommence in 2026.
After Travere Therapeutics announced a voluntary pause in the Phase 3 HARMONY study for pegtibatinase in the treatment of classical homocystinuria, or HCU, it is anticipated that the timeline for broader patient enrollment and eventual commercialization will be significantly extended. It is now expected that study enrollment will recommence in 2026. Consequently, there has been a modest adjustment in the perceived probability of success for pegtibatinase, now estimated at 60%, and a corresponding two-year postponement in the projected sales timeline.
Here are the latest investment ratings and price targets for $Travere Therapeutic (TVTX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間9月27日，多家華爾街大行更新了$Travere Therapeutic (TVTX.US)$的評級，目標價介於18美元至23美元。
美銀證券分析師Jason Zemansky維持買入評級，並將目標價從19美元下調至18美元。
花旗分析師Yigal Nochomovitz維持買入評級，並將目標價從23美元下調至19美元。
Guggenheim分析師Vamil Divan維持買入評級，並將目標價從25美元下調至23美元。
H.C. Wainwright分析師Ed Arce維持買入評級，並將目標價從23美元下調至18美元。
此外，綜合報道，$Travere Therapeutic (TVTX.US)$近期主要分析師觀點如下：
Travere Therapeutics最近宣佈，出於製造方面的考慮，其聚乙二醇酶3期HARMONY研究的註冊暫停。這一事態發展被視爲商業投資組合的延遲，該公司預計最早可能在2026年恢復試驗。儘管遇到了挫折，但該計劃的價值已經微乎其微，該公司的管理層已經表示，暫停不太可能影響試驗的設計和註冊。因此，預計短期內對市場情緒的預期影響將是有限的。
Travere Therapeutics宣佈自願暫停其聚乙二醇酶的3期HARMONY研究的入組，原因是生產規模擴大面臨的挑戰。鑑於聚乙二醇酶有望將公司的產品組合擴展到Filspari以外，這一發展被視爲挫折。預期的市場引入現已調整爲2030財年，前提是入學將於2026年重新開始。
在Travere Therapeutics宣佈自願暫停用於治療傳統高胱氨酸尿症（HCU）的聚乙二醇酶的三期HARMONY研究之後，預計擴大患者入組和最終商業化的時間表將大大延長。現在預計研究招生將在2026年重新開始。因此，pegtibatinase的預期成功概率略有調整，目前估計爲60％，預計銷售時間表也相應推遲了兩年。
以下爲今日4位分析師對$Travere Therapeutic (TVTX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
